Clinical value of HR-HPV E6/E7 DNA and mRNA for cervical disease screening

Wang Ya, He Min

PDF(642 KB)
PDF(642 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (12) : 1594-1599. DOI: 10.13406/j.cnki.cyxb.003679
Clinical research

Clinical value of HR-HPV E6/E7 DNA and mRNA for cervical disease screening

Author information +
History +

Abstract

Objective To determine the clinical value of high-risk human papillomavirus（HR-HPV） E6/E7 DNA and mRNA for cervical disease screening. Methods We retrospectively analyzed 754 patients’ results of HR-HPV E6/E7 DNA testing，E6/E7 mRNA testing，liquid-based cytology（LBC），colposcopy，and histopathological examination. The positive rates of E6/E7 DNA and E6/E7 mRNA by cytological diagnosis and histopathological diagnosis were compared. With histopathological diagnosis as the gold standard，the value of E6/E7 DNA and E6/E7 mRNA for detecting high-grade squamous intraepithelial lesions or severer conditions（HSIL+） was evaluated. Results Among the 754 patients，the detection rates of HR-HPV E6/E7 DNA and E6/E7 mRNA were 24.80% and 17.9%，respectively，in which HPV52，58，and 16 were most common. The positive rates of E6/E7 DNA and E6/E7 mRNA increased as cytological and histopathological grades increased. The positive rates of E6/E7 DNA and E6/E7 mRNA in patients with HSIL（+） （93.75%，15/16；100%，16/16） were significantly higher than those in patients with LSIL（-）（23.30%，172/738；16.12%，119/738），which were all significantly higher than the positive rates of LBC in patients with HSIL（+） and those with LSIL（-）（81.25%，13/16；5.56%，41/738；P<0.01）. For detecting HSIL（+），E6/E7 DNA，E6/E7 mRNA，E6/E7 DNA+LBC，and E6/E7 mRNA+LBC showed similar high sensitivities（93.80%，93.80%，100%，and 100%，respectively） and negative predictive values（99.80%，99.80%，100.00%，and 100.00%，respectively；P>0.05）. E6/E7 mRNA and E6/E7 mRNA+LBC were superior to E6/E7 DNA and E6/E7 DNA+LBC in terms of specificity，positive predictive value，the Yoden index，and the area under the receiver operating characteristic curve（P<0.01），and there were no significant differences between E6/E7 DNA and E6/E7 mRNA alone and their combinations with LBC（P>0.05）. Conclusion HR-HPV E6/E7 DNA and E6/E7 mRNA are related to the severity of cervical lesions，both with high diagnostic efficacy for HSIL（+） screening，and HR-HPV E6/E7 mRNA is superior to E6/E7 DNA.

Key words

E6/E7 DNA / E6/E7 mRNA / high-risk human papillomavirus / cervical lesion

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Wang Ya , He Min. Clinical value of HR-HPV E6/E7 DNA and mRNA for cervical disease screening. Journal of Chongqing Medical University. 2024, 49(12): 1594-1599 https://doi.org/10.13406/j.cnki.cyxb.003679

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Siegel RL， Miller KD， Jemal A. Cancer statistics，2016[J]. CA Cancer J Clin，2016，66（1）：7-30．
本文引用 [1]
2
Qi JL， Li ML， Wang LJ，et al. National and subnational trends in cancer burden in China，2005-20：an analysis of national mortality surveillance data[J]. Lancet Public Health，2023，8（12）：e943-e955．
本文引用 [1]
3
刘玲玲，李　丽，王丽凤，等. 宫颈细胞学质量控制及漏诊原因分析[J]. 中国药物与临床，2019，19（3）：504-506．
Liu LL， Li L， Wang LF，et al. Quality control of cervical cytology and analysis of reasons for missed diagnosis[J]. Chin Remedies Clin，2019，19（3）：504-506．
本文引用 [1]
4
国家卫生健康委员会. 《宫颈癌筛查工作方案》[EB/OL]. [2021‑12‑31].
http://www.nhc.gov.cn/fys/s3581/202201/cad44d88acca4ae49e12dab9176ae21c.shtml
National Health Commission Cervical Cancer Screening Work Plan [EB/OL] [2021‑12‑31].
http://www.nhc.gov.cn/fys/s3581/202201/cad44d88acca4ae49e12dab9176ae21c.shtml
本文引用 [1]
5
中华预防医学会肿瘤预防与控制专业委员会，中国医师协会妇产科医师分会阴道镜与宫颈病变专业委员会，中国优生科学协会阴道镜和子宫颈病理学分会，等. 人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识（2022）[J]. 中华医学杂志，2023，103（16）：1184-1195．
Cancer Prevention and Control Professional Committee of the Chinese Preventive Medicine Association, Vaginal Endoscopy and Cervical Disease Professional Committee of the Obstetrics and Gynecology Branch of the Chinese Medical Association, Vaginal Endoscopy and Cervical Pathology Branch of the Chinese Eugenics Association, etc ． Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening（2022）[J]. Natl Med J China，2023，103（16）：1184-1195．
本文引用 [4]
6
Schiffman M， Castle PE， Jeronimo J，et al. Human papillomavirus and cervical cancer[J]. Lancet，2007，370（9590）：890-907．
本文引用 [1]
7
Della Fera AN， Warburton A， Coursey TL，et al. Persistent human papillomavirus infection[J]. Viruses，2021，13（2）：321．
本文引用 [2]
8
Harlfinger J， Sommer I， Gartlehner G. WHO guideline for screening and treatment of cervical pre-cancerous lesions for cervical cancer prevention（second edition）[J]. Gesundheitswesen，2023，85（7）：630-634．
本文引用 [2]
9
Nayar R， Wilbur DC. The Pap test and Bethesda 2014[J]. Cancer Cytopathol，2015，123（5）：271-281．
本文引用 [1]
10
Kurman RJ， Carcangiu ML， Herrington CS，et al. WHO Classification of Tumours of Female Reproductive Organs[M]. 4th ed. Lyon: IARC，2014.
本文引用 [1]
11
McBride AA. Human papillomaviruses：diversity，infection and host interactions[J]. Nat Rev Microbiol，2022，20（2）：95-108．
本文引用 [2]
12
de Villiers EM， Fauquet C， Broker TR，et al. Classification of papillomaviruses[J]. Virology，2004，324（1）：17-27．
本文引用 [1]
13
Tjalma WA， Depuydt CE. Cervical atypical glandular cells and false negative HPV testing：a dramatic reality of the wrong test at the right place[J]. Eur J Gynaecol Oncol，2014，35（2）：117-120．
本文引用 [2]
14
Morris BJ. Cervical human papillomavirus screening by PCR：advantages of targeting the E6/E7 region[J]. Clin Chem Lab Med，2005，43（11）：1171-1177．
本文引用 [2]
15
Arbyn M， Simon M， Peeters E，et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening[J]. Clin Microbiol Infect，2021，27（8）：1083-1095．
本文引用 [3]
16
刘晓旭，梁建梅，苏学艳，等. HPV DNA和HPV E6/E7 mRNA检测在宫颈病变诊治中应用价值的比较[J]. 国际妇产科学杂志，2021，48（4）：462-466．
Liu XX， Liang JM， Su XY，et al. Comparison of the application value of HPV E6/E7 mRNA and HPV DNA detection in the diagnosis and treatment of cervical lesions[J]. J Int Obstet Gynecol，2021，48（4）：462-466．
本文引用 [1]
17
陆　璐，成　建. 人乳头瘤病毒DNA基因分型和E6/E7 mRNA检测在宫颈癌筛查中的临床价值[J]. 南京医科大学学报（自然科学版），2021，41（1）：122-125．
Lu L， Cheng J. Clinical value of human papillomavirus DNA genotyping and E6/E7 mRNA detection in cervical cancer screening[J]. J Nanjing Med Univ Nat Sci，2021，41（1）：122-125．
18
Yang ZJ， Zhu WP， Liu Y，et al. Performance of aptima HPV E6/E7 mRNA test for detection of cervical lesions in a large Chinese population[J]. Iran J Public Health，2022，51（11）：2549-2554．
本文引用 [3]
19
Zhu B， Liu YY， Zuo TT，et al. The prevalence，trends，and geographical distribution of human papillomavirus infection in China：the pooled analysis of 1.7 million women[J]. Cancer Med，2019，8（11）：5373-5385．
本文引用 [1]
20
李　乐，王　瑞. 14962例体检女性HPV感染特征及联合TCT筛查宫颈病变的价值[J]. 第三军医大学学报，2020，42（15）：1548-1554．
Li L， Wang R. Characteristics of HPV infection and value of its combination with TCT in screening cervical lesions：report based on 14 962 women taking physical examination[J]. J Third Mil Med Univ，2020，42（15）：1548-1554．
本文引用 [1]
21
方　莉，叶　红，许媛，等. 四川东北部地区女性高危型人乳头瘤病毒感染情况分析[J]. 检验医学与临床，2017，14（3）：352-354．
Fang L， Ye H， Xu Y，et al. An investigation of high risk types of HPV infection among women in Northeast of Sichuan[J]. Lab Med Clin，2017，14（3）：352-354．
本文引用 [1]
22
黄珊珊，徐凤娟，成　雁，等. 高危型HPV E6/E7 mRNA与HC2 HPV-DNA联合检测在宫颈病变筛查中价值[J]. 中华实用诊断与治疗杂志，2020，34（6）：577-580．
Huang SS， Xu FJ， Cheng Y，et al. Joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA in cervical lesions screening[J]. J Chin Pract Diagn Ther，2020，34（6）：577-580．
本文引用 [1]
23
顾丽萍，周雪娟，王丹丹，等. 高危型人乳头瘤病毒阳性患者2943例阴道镜病理结果分析[J]. 中国实用妇科与产科杂志，2023，39（12）：1233-1236．
Gu LP， Zhou XJ， Wang DD，et al. Analysis of colposcopic pathologic findings in 2943 cases of high-risk human papillomavirus-positive patients[J]. Chin J Pract Gynecol Obstet，2023，39（12）：1233-1236．
本文引用 [1]
24
Liu JX， Yang T， Hu YB，et al. The value of HPV E6/E7 mRNA quantitative analysis in distinguishing high-grade cervical squamous intraepithelial lesions from low-grade cervical squamous intraepithelial lesions[J]. J Virol Methods，2021，289：114014．
本文引用 [1]

Comments

PDF(642 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉